Advertisement

Topics

Loxo Oncology, Inc. Company Profile

09:48 EST 14th December 2018 | BioPortfolio

Loxo Oncology was incorporated in Delaware in May 2013 and was founded by Josh Bilenker, M.D., a partner at Aisling Capital. Loxo Oncology is committed to bringing targeted cancer therapies rapidly into the clinic that have an opportunity for outsized clinical effects in genetically defined patient populations. Loxo Oncology derives its company name from an attendant of the Greek goddess Artemis, who represented the concept of trajectory in the sport of archery.


News Articles [558 Associated News Articles listed on BioPortfolio]

License Agreement: Array Biopharma, $ARRY (Loxo Oncology, $LOXO)

July 2013, Array BioPharma (ARRY) entered into a Drug Discovery Collaboration Agreement with Loxo Oncology (LOXO) @LoxoOncology, and granted Loxo exclusive rights to develop and commercialize certain ...

Bayer-Partner Loxo Oncology: Das passt

Loxo Oncology hat in diesem Jahr mit dem RET-Inhibitor LOXO-292 bereits auf dem ASCO-Meeting für Furore gesorgt. Der Wirkstoff, der gegen nicht kleinzelligem Lungenkrebs entwickelt wird, konnte nun.....

Loxo Oncology: Mutige Anleger greifen zu

Kulmbach (www.aktiencheck.de) - Loxo Oncology-Aktienanalyse von "Der Aktionär": Michel Doepke, Redakteur des Anlegermagazins "Der Aktionär", rät in einer aktuellen Aktienanalyse die Loxo Oncology-A...

Loxo Oncology: Abwärtstrend gebrochen

Kulmbach (www.aktiencheck.de) - Loxo Oncology-Aktienanalyse von "Der Aktionär": Michel Doepke, Redakteur des Anlegermagazins "Der Aktionär", nimmt in einer aktuellen Aktienanalyse die Loxo Oncology....

Bayer-Partner Loxo Oncology: Das ist eine Kampfansage

Auf dem diesjährigen ESMO-Kongress in München hat Loxo Oncology Updates zu den laufenden Projekten LOXO-292 und Larotrectinib präsentiert. Letzteres ist für den DAX-Konzern Bayer von enormer Bedeu...

Loxo Oncology Announces Larotrectinib Update In Patients With TRK Fusion Cancers

LEVERKUSEN (dpa-AFX) - Loxo Oncology, Inc. (LOXO) and Bayer AG announced updated clinical data for larotrectinib, an investigational oral, selective, and CNS-active TRK inhibitor, in adult and ped...

FDA Grants Breakthrough Therapy Designation to Loxo Oncology’s Investigational LOXO-292 for RET Fusion-Positive Thyroid Cancer

STAMFORD, Conn., Oct. 15, 2018 (GLOBE NEWSWIRE) — Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company developing highly selective medicines for patients with genomically defined c...

Loxo Oncology Announces Positive Interim Clinical Data from LOXO-292 Dose Escalation Trial in RET-Altered Cancers Presented at the American Society of Clinical Oncology Annual Meeting

– 77% Overall Response Rate in RET Fusion Cancers and 45% Overall Response Rate in RET Mutated Medullary Thyroid Cancer (MTC) – – Activity Observed Independent of RET Alteration, Tumo...

PubMed Articles [1288 Associated PubMed Articles listed on BioPortfolio]

LOXO-292 Reins In RET-Driven Tumors.

LOXO-292, a selective and potent RET inhibitor, led to tumor shrinkage in fusion-positive and -mutant cancers alike, according to phase I data reported at the 2018 American Society of Clinical Oncolo...

Share of Oncology Versus Nononcology Spending in Episodes Defined by the Centers for Medicare & Medicaid Services Oncology Care Model.

Performance-based payments to oncology providers participating in the Centers for Medicare & Medicaid Services (CMS) Oncology Care Model (OCM) are based, in part, on overall spending in 6-month episod...

Burnout and Resiliency in Canadian Oncology Residents: a Nationwide Resident and Program Director Survey.

To measure burnout rates and resiliency scores in Canadian Oncology residents and to advance the knowledge regarding resiliency and wellness training in Canadian Oncology residency programs.

Development of a Virtual Radiation Oncology Clinic for training and simulation of errors in the radiation oncology workflow.

Integrative Oncology Scholars Program: A Model for Integrative Oncology Education.

Oncology providers are often confronted by patients who use complementary or alternative therapies, but have limited knowledge or confidence on how to advise patients on appropriate use. Despite this,...

Clinical Trials [567 Associated Clinical Trials listed on BioPortfolio]

A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

This is an open-label, multi-center Phase 1/2 study of oral LOXO-305 in patients with CLL/SLL and NHL who have failed or are intolerant to standard of care.

Expanded Access to Provide LOXO-195 for the Treatment of Cancers With a NTRK Gene Fusion

LOXO-195 expanded access is for patients with cancer with a NTRK1, NTRK2, or NTRK3 gene fusion who are ineligible for an ongoing LOXO-195 clinical trial or have other considerations that p...

Oral TRK Inhibitor LOXO-101 for Treatment of Advanced Pediatric Solid or Primary Central Nervous System Tumors

This is a multicenter, open-label, Phase 1 study in pediatric patients with advanced solid or primary CNS tumors. LOXO‑101 will be administered orally (PO) twice daily (BID), with the do...

Expanded Access to Provide Larotrectinib (LOXO-101) for the Treatment of Cancers With a NTRK Gene Fusion

Larotrectinib (LOXO-101) expanded access is for patients with cancer with a NTRK1, NTRK2, or NTRK3 gene fusion who are ineligible for an ongoing larotrectinib (LOXO-101) clinical trial or ...

Phase 1/2 Study of LOXO-195 in Patients With Previously Treated NTRK Fusions or Non-fusion NTRK Cancers

This is a Phase 1/2, multi-center, open-label study designed to evaluate the safety and efficacy of LOXO-195 when administered orally to patients with NTRK fusion cancers treated with prio...

Companies [747 Associated Companies listed on BioPortfolio]

Loxo Oncology, Inc.

Loxo Oncology was incorporated in Delaware in May 2013 and was founded by Josh Bilenker, M.D., a partner at Aisling Capital. Loxo Oncology is committed to bringing targeted cancer...

Takeda Oncology

Takeda Oncology, headquartered in Cambridge, MA, delivers novel medicines to patients with cancer worldwide through its commitment to science, breakthrough innovation and passion ...

OncLive

OncLive is the official website for Intellisphere’s Oncology Specialty Group, which publishes Oncology & Biotech News, OncologyLive, Oncology Nursing News, and Contemporary O...

Cold Spring Publishing, LLC

Cold Spring Publishing, LLC, (CSP) is a medical publishing company whose principals have more than 50 years of combined publishing experience, with a specific focus in oncology. CSP publishes JNCCN --...

Michiana Hematology-Oncology,P.C.

Michiana Hematology-Oncology,P.C. is the premier provider of medical oncology, gynecologic oncology and adult hematology services in North-Central Indiana and Southwestern Lower Michigan.Michiana Hema...

More Information about "Loxo Oncology, Inc." on BioPortfolio

We have published hundreds of Loxo Oncology, Inc. news stories on BioPortfolio along with dozens of Loxo Oncology, Inc. Clinical Trials and PubMed Articles about Loxo Oncology, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Loxo Oncology, Inc. Companies in our database. You can also find out about relevant Loxo Oncology, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...


Corporate Database Quicklinks



Searches Linking to this Company Record